Compounding guides
Peptide compounding: questions clinics should ask
A clinic-focused guide to discussing peptide identity, current compounding eligibility, prescriptions, labeling and pharmacy coordination before accepting a proposed preparation.
By Liberty Compounding Pharmacy
Published · 3 min read
Ask about the exact substance, not just “peptides”
“Peptide” describes a broad category. It does not tell a clinic whether a particular drug product is FDA-approved, whether a proposed compounded preparation is eligible under the applicable framework, or whether a pharmacy can accept a specific prescription. Begin with the exact ingredient, chemical form, dosage form and proposed route.
Keep an FDA-approved drug product separate from a compounded preparation in both procurement discussions and patient communications. Compounded drugs are not FDA-approved. A supplier’s product listing or a request from a patient does not establish that a preparation can be compounded or is appropriate for that patient.
Request a current, substance-specific eligibility review
FDA describes several pathways for bulk drug substances used under section 503A, including applicable compendial monographs, components of FDA-approved drugs and the 503A bulks list. Interim policies also need careful review. A nomination, an advisory discussion and a final listing are different steps; ask which current provision or policy the pharmacy is relying on.
There is a recent development to account for. On October 30, 2026, HHS published notice of a draft, conditional enforcement-discretion policy addressing six peptide bulk substances while rulemaking proceeds. The HHS document covers specified identities and routes and includes conditions involving sourcing, characterization, labeling, reporting and patient-specific prescriptions. It does not establish FDA approval or make all peptide preparations available.
If a pharmacy relies on that policy, ask it to identify the precise substance and explain how the proposed preparation fits every relevant condition. Confirm applicable state requirements separately. Sources were checked on November 7, 2026; review the current policy again when evaluating an actual request.
Discuss safety information alongside eligibility
FDA’s safety-risk page identifies concerns for a number of peptide bulk substances, including immune reactions, peptide-related impurities, characterization difficulties and limited human safety information. Entries have different statuses and routes. Avoid treating a change in list status as a conclusion that an ingredient has been proven safe or effective.
The clinical question and the compounding question both need an answer. Ask the prescriber to address the patient’s medical need and available evidence, and ask the pharmacist to review the specific preparation and applicable requirements. Neither review should be replaced by a general “peptide program” description.
Make the clinic–pharmacy handoff concrete
Before coordinating any prescription, clarify the following with the responsible pharmacy:
- Which facility would compound the preparation, and who would dispense it?
- What patient-specific prescription and supporting information are needed?
- How will the ingredient identity, concentration, dosage form and directions be confirmed?
- Who will provide labeling, storage instructions, the beyond-use date and patient counseling?
- Who will assess a product complaint, communicate with the prescriber and handle any required reporting?
Keep the inquiry separate from an availability promise
A general peptide discussion should lead to an ingredient-specific review. Ask about the exact preparation, the patient’s circumstances and the destination before communicating availability. An ingredient guide does not replace the dispensing pharmacist’s assessment of a request.
For an initial Liberty clinic inquiry, call (888) 448-0549 or email contact@libertycompounding.com. Ask how to share any subsequent prescription information through the pharmacy’s appropriate channel; keep patient details out of an initial general inquiry.